Share
Export Citation
Effectiveness of tamsulosin administration on the degree of bladder mucosal inflammation in patients following ureteral stent placement: a randomized controlled trial study
Pratiwi J.D.
Chirurgia Turin
Q4Abstract
BACKGROUND: Ureteral stents are effective in maintaining kidney function and ureteral patency but are commonly associated with side effects, collectively referred to as Stent-Related Syndrome (SRS). These include urinary discomfort, pain, and reduced quality of life. This study aimed to evaluate the effectiveness of tamsulosin (0.4 mg) in reducing bladder mucosal inflammation and improving symptoms following ureteral stent placement.METHODS: A randomized controlled trial study was conducted in patients undergoing routine ureteral stent placement after ureteroscopic lithotripsy (URSL). Participants were divided into two groups: Group A (tamsulosin) and Group B (placebo). Histopathological changes in bladder mucosa, as well as blood and urine samples, were analyzed over 6 weeks.RESULTS: The study included 27 participants (66.7% male, aged 21-67 years). The group treated with tamsulosin (0.4 mg/day) demonstrated significant improvement in urinary symptoms as assessed by the Ureteral Stent Symptoms Questionnaire (USSQ) over 6 weeks. Histopathological analysis revealed a reduction in bladder mucosal inflammation in the tamsulosin group, whereas inflammation worsened in the placebo group.CONCLUSIONS: Tamsulosin (0.4 mg) effectively reduced bladder mucosal inflammation and alleviated lower urinary tract symptoms (LUTS) in patients after ureteral stent placement, while the placebo group showed no significant improvement, and an increase in bladder inflammation.